Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

Inclusion Criteria:

- Adult patients, at least 18 years of age

- History of histologically confirmed NHL as assessed per medical record review.

- At least one site of measurable disease (per RECIST 1.1) that is seen on CT, MRI, or
FDG PET/CT.

- Recommended to start lenalidomide.

- Participants must be informed of the investigational nature of this study and provide
written informed consent in accordance with institutional and federal guidelines prior
to study-specific procedures.

Exclusion Criteria:

- Females who are pregnant or breast-feeding at the time of screening will not be
eligible for this study. Female participants of child-bearing potential will have a
urine or serum pregnancy test at the time of the screening visit.

- Inability to tolerate imaging procedures in the opinion of the investigator or
treating physician.

- Serious or unstable medical or psychological conditions that, in the opinion of the
investigator would compromise the subject's safety or successful participation in the
study.